GGHC
LPCN icon

Gilder Gagnon Howe & Co’s Lipocine LPCN Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-23,812
Closed -$1.23M – 280
2016
Q2 		$1.23M Sell
23,812
-14,682
-38% -$2.27M 0.02% 179
2016
Q1 		$6.64M Buy
38,494
+8,925
+30% +$1.52M 0.13% 98
2015
Q4 		$6.5M Sell
29,569
-1,166
-4% -$245K 0.1% 107
2015
Q3 		$6.18M Buy
+30,735
New +$7.11M 0.1% 122

Other funds holding LPCN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Gilder Gagnon Howe & Co's LPCN Position: Q3 2016 in Review

Gilder Gagnon Howe & Co sold out of Lipocine (LPCN) in Q3 2016, closing a stake of 23,812 shares — an estimated $1.23M sold.

Gilder Gagnon Howe & Co first reported a position in LPCN in Q3 2015 and held it in 4 quarters. The position peaked at $6.64M in Q1 2016. 47 funds tracked by Wall St. Rank hold LPCN as of Q3 2016.

  • Gilder Gagnon Howe & Co reported no remaining Lipocine position as of Q3 2016 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 23,812 Lipocine shares in Q3 2016, an estimated $1.23M.
  • Gilder Gagnon Howe & Co first reported a position in Lipocine in Q3 2015 and held it in 4 quarters.
  • Gilder Gagnon Howe & Co's Lipocine position peaked at $6.64M in Q1 2016.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q3 2016.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2016, filed 1 Nov 2016.